Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types

J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, D G Kieback, S B Kaye, L Gianni, A Harris, Thomas Björk, S D Averbuch, A Feyereislova, H Swaisland, F Rojo, J Albanell

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

770 Citeringar (SciVal)

Fingeravtryck

Fördjupa i forskningsämnen för ”Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types”. Tillsammans bildar de ett unikt fingeravtryck.

Medicin och livsvetenskap